Australian researchers reported that they were able to target prostate cancer cells by using a drug that specifically triggers the prostate's beta estrogen receptor cells. They said activating the estrogen cells appears to induce a small cluster of treatment-resistant cells in prostate tumors to undergo cell death.

Related Summaries